These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 33253353)

  • 1. Drug repurposing for COVID-19: could vitamin C combined with glycyrrhizic acid be at play by the findings of Li et al.'s database-based network pharmacology analysis?
    Huang YX; Wang WX; Tang YP; Yue SJ
    Brief Bioinform; 2021 Mar; 22(2):1508-1510. PubMed ID: 33253353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative pharmacological mechanism of vitamin C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses.
    Li R; Wu K; Li Y; Liang X; Lai KP; Chen J
    Brief Bioinform; 2021 Mar; 22(2):1161-1174. PubMed ID: 32662814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycyrrhizin as a Potential Treatment for the Novel Coronavirus (COVID-19).
    Al-Kamel H; Grundmann O
    Mini Rev Med Chem; 2021; 21(16):2204-2208. PubMed ID: 33568033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis.
    Chen L; Hu C; Hood M; Zhang X; Zhang L; Kan J; Du J
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32344708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
    Verma AK; Aggarwal R
    Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycyrrhizin: An old weapon against a novel coronavirus.
    Chrzanowski J; Chrzanowska A; Graboń W
    Phytother Res; 2021 Feb; 35(2):629-636. PubMed ID: 32902005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
    Akilesh SM; J R; Palanisamy D; Wadhwani A
    Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review on drug repurposing applicable to COVID-19.
    Dotolo S; Marabotti A; Facchiano A; Tagliaferri R
    Brief Bioinform; 2021 Mar; 22(2):726-741. PubMed ID: 33147623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Potential of Glycyrrhizinate in the Management of COVID-19: A Systematic Review of the Efficacy and Safety of Glycyrrhizin Preparations in the Treatment of SARS and MERS.
    Li H; Hu Y; Tang H; Li S; Ding H; Zhai S; Zhao R
    Am J Chin Med; 2020; 48(7):1539-1552. PubMed ID: 33202150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19?
    Feyaerts AF; Luyten W
    Nutrition; 2020; 79-80():110948. PubMed ID: 32911430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.
    Sanghai N; Shafiq K; Tranmer GK
    Mini Rev Med Chem; 2021; 21(1):3-9. PubMed ID: 32838716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19.
    Luo P; Liu D; Li J
    Int J Antimicrob Agents; 2020 Jun; 55(6):105995. PubMed ID: 32335281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing Methotrexate in Dampening SARS-CoV2-S1-Mediated IL6 Expression: Lessons Learnt from Lung Cancer.
    Gowda P; Patrick S; Joshi SD; Kumawat RK; Sen E
    Inflammation; 2022 Feb; 45(1):172-179. PubMed ID: 34480250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilizing clinical pharmacology in the drug repurposing arena: a look into COVID-19.
    Ruggiero R; Balzano N; Di Napoli R; Sullo MG; Rossi F; Capuano A; Rafaniello C
    Expert Rev Clin Pharmacol; 2022 Oct; 15(10):1225-1231. PubMed ID: 36196903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?
    Bailly C; Vergoten G
    Pharmacol Ther; 2020 Oct; 214():107618. PubMed ID: 32592716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing.
    Glebov OO
    FEBS J; 2020 Sep; 287(17):3664-3671. PubMed ID: 32428379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing Ayush-64 for COVID-19: A Computational Study Based on Network Pharmacology and Molecular Docking.
    K C M; K A AN
    Comb Chem High Throughput Screen; 2022; 25(12):2089-2102. PubMed ID: 35142268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug repositioning by merging active subnetworks validated in cancer and COVID-19.
    Lucchetta M; Pellegrini M
    Sci Rep; 2021 Oct; 11(1):19839. PubMed ID: 34615934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic.
    Khadka S; Yuchi A; Shrestha DB; Budhathoki P; Al-Subari SMM; Ziad Alhouzani TM; Anwar Butt I
    Altern Ther Health Med; 2020 Aug; 26(S2):100-107. PubMed ID: 32827400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROMISCUOUS 2.0: a resource for drug-repositioning.
    Gallo K; Goede A; Eckert A; Moahamed B; Preissner R; Gohlke BO
    Nucleic Acids Res; 2021 Jan; 49(D1):D1373-D1380. PubMed ID: 33196798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.